Table 1

Participant characteristics at baseline assessment

Normal Weight (n = 16)

Obese (n = 16)

+IR

-IR

+IR

-IR


N (females)

8 (5)

8 (5)

8 (6)

8 (6)

Anti-TNF╬▒ agent (Infliximab/Etanercept/Adalimumab)

5/3/0

4/3/1

6/2/0

5/3/0

Smokers (current; ex)

3 (1; 2)

4 (1; 3)

3 (2; 1)

4 (2; 2)

Age (years)

60.8

62.2

58.6

60.8

(6.9)

(7.8)

(6.7)

(8.0)

Height (cm)

165.9

167

165.4

165.2

(10.6)

(12.2)

(11.9)

(9.4)

Weight (kg)

60.3

61.6

88.9

89.8

(6.4)

(7.2)

(10.1)

(9.6)

BMI (kg/m2)

21.8

22.1

32.3

32.8

(2.4)

(2.2)

(3.0)

(3.1)

HOMA

2.9

2.2*

3.1

2.1#

(0.7)

(0.4)

(0.5)

(0.8)

QUICKI

0.29

0.36*

0.30

0.37#

(0.02)

(0.03)

(0.03)

(0.01)

HAQ

1.6

1.8

1.7

2.0

(0.3)

(0.2)

(0.4)

(0.5)

DAS

5.7

5.9

6.2

6.1

(0.7)

(0.5)

(1.0)

(0.6)

ESR (mm/h)

31

38

35

43

(7.5)

(10)

(9.5)

(12.5)

CRP (mg/L)

29

32.5

31.4

34.2

(6.4)

(8.2)

(8.8)

(7.4)

Disease Duration

9.1

8.6

8

10.2

(years)

(2.5)

(2.3)

(3.6)

(4.7)


* Significantly different compared to N+IR (P < 0.05). # Significantly different compared to O+IR (P < 0.05). BMI, body mass index; CRP, C-reactive protein; DAS, disease activity score 28; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; +IR, with insulin resistance; -IR, without insulin resistance; HOMA, Homeostasis Model Assessment Of Insulin Resistance; QUICKI, Quantitative Insulin Sensitivity Check Index

Stavropoulos-Kalinoglou et al. Arthritis Research & Therapy 2012 14:R160   doi:10.1186/ar3900

Open Data